Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level

Saloua Benmansour, Marco Cecchi, David A. Morilak, Greg A. Gerhardt, Martin A. Javors, Georgianna G. Gould, Alan Frazer

Research output: Contribution to journalArticle

  • 226 Citations

Abstract

To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([3H]CN-IMI), was decreased by 80-90% in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression.

LanguageEnglish (US)
Pages10494-10501
Number of pages8
JournalJournal of Neuroscience
Volume19
Issue number23
StatePublished - Dec 1 1999

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Serotonin Uptake Inhibitors
Antidepressive Agents
Phenelzine
Messenger RNA
Serotonin
Paroxetine
Desipramine
Fluvoxamine
Sertraline
Hippocampus
Down-Regulation
Raphe Nuclei
Monoamine Oxidase Inhibitors
Autoradiography
Norepinephrine
Gene Expression
Brain
Pharmaceutical Preparations

Keywords

  • [H]CN- IMI binding
  • Antidepressants
  • Dorsal hippocampus
  • In vivo electrochemistry
  • mRNA for the SERT
  • Serotonin transporter

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. / Benmansour, Saloua; Cecchi, Marco; Morilak, David A.; Gerhardt, Greg A.; Javors, Martin A.; Gould, Georgianna G.; Frazer, Alan.

In: Journal of Neuroscience, Vol. 19, No. 23, 01.12.1999, p. 10494-10501.

Research output: Contribution to journalArticle

@article{ffa4f563024c48659bb89af3dba771b9,
title = "Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level",
abstract = "To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([3H]CN-IMI), was decreased by 80-90{\%} in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression.",
keywords = "[H]CN- IMI binding, Antidepressants, Dorsal hippocampus, In vivo electrochemistry, mRNA for the SERT, Serotonin transporter",
author = "Saloua Benmansour and Marco Cecchi and Morilak, {David A.} and Gerhardt, {Greg A.} and Javors, {Martin A.} and Gould, {Georgianna G.} and Alan Frazer",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "19",
pages = "10494--10501",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "23",

}

TY - JOUR

T1 - Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level

AU - Benmansour, Saloua

AU - Cecchi, Marco

AU - Morilak, David A.

AU - Gerhardt, Greg A.

AU - Javors, Martin A.

AU - Gould, Georgianna G.

AU - Frazer, Alan

PY - 1999/12/1

Y1 - 1999/12/1

N2 - To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([3H]CN-IMI), was decreased by 80-90% in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression.

AB - To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([3H]CN-IMI), was decreased by 80-90% in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression.

KW - [H]CN- IMI binding

KW - Antidepressants

KW - Dorsal hippocampus

KW - In vivo electrochemistry

KW - mRNA for the SERT

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=0033507575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033507575&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 10494

EP - 10501

JO - Journal of Neuroscience

T2 - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 23

ER -